Guardant Health, Inc.
GH
Rankning i aktier
#1100
Guardant Health, Inc., established in Redwood City, California, in 2011, is a... Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Aktiekurs
$157.94
Senast synkroniserad: 2026-10-16
Marknadsvärde
$21.19B
Förändring (1 dag)
-4.79%
Förändring (1 år)
141.28%
Land
US
Handel Guardant Health, Inc. (GH)
Kategori
Healthcare
Rörelsemarginal för Guardant Health, Inc. (GH)
Rörelsemarginal per October 2026 TTM: -39.75%
Enligt de senaste finansiella rapporterna och aktiekursen för Guardant Health, Inc. är företagets nuvarande rörelsemarginal (TTM) -39.75%. Vid slutet av 2023 var rörelsemarginalen -100.14%.
Historik för rörelsemarginal för Guardant Health, Inc. från 2016 till 2026
Rörelsemarginal vid slutet av varje år
| År | Rörelsemarginal | Ändra |
|---|---|---|
| 2026 (TTM) | -39.75% | -33.77% |
| 2024 | -60.02% | -40.06% |
| 2023 | -100.14% | -17.31% |
| 2022 | -121.10% | 10.09% |
| 2021 | -110.00% | 23.71% |
| 2020 | -88.92% | 131.44% |
| 2019 | -38.42% | -62.53% |
| 2018 | -102.54% | -33.29% |
| 2017 | -153.71% | -11.49% |
| 2016 | -173.66% | 0.00% |
Rörelsemarginal för liknande företag eller konkurrenter
| Företag | Rörelsemarginal | Skillnad i rörelsemarginal | Land |
|---|---|---|---|
| 17.97% | -100.45% |
US
|
|
| 20.42% | -100.51% |
US
|
|
| -10.70% | -99.73% |
US
|
|
| 0.00% | - |
CN
|
|
| 22.23% | -100.56% |
US
|
Vad är ett företags Rörelsemarginal?
Rörelsemarginal är en viktig indikator för att bedöma ett företags lönsamhet. Högre Rörelsemarginals är generellt bättre eftersom de visar att ett företag kan sälja sina produkter eller tjänster för betydligt mer än produktionskostnaden. Rörelsemarginal beräknas genom att dividera företagets vinst med dess intäkter.